Brain scans reveal how a calming drug affects emotion in psychosis
NCT ID NCT04004416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates how a medication called lorazepam, which boosts the calming brain chemical GABA, changes emotional brain activity in people with psychosis. Participants aged 16–60 with conditions like schizophrenia or bipolar disorder, along with healthy volunteers, will undergo brain scans after taking either lorazepam or a placebo. The goal is to better understand the role of GABA in emotional processing and mental illness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lorazepam
What this could lead to
If successful, this could reveal how brain chemistry differs in psychosis, pointing toward better-targeted treatments for emotional symptoms.
What could go wrong
This is an early-phase observational study, not a treatment trial. Lorazepam is used only as a probe, and results may not lead directly to new therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States